Abstract
Background/Objectives Glioblastoma is the most common primary malignant brain tumor in adults, with a particularly high incidence among individuals aged 65 and older. Older patients often experience worse outcomes due to limited treatment options, comorbidities, and frailty. This study investigates the impact of radiation therapy and genomic factors on survival outcomes in older glioblastoma patients, aiming to inform treatment strategies for this vulnerable population.
Methods We analyzed clinical and genomic data from 109 glioblastoma patients aged 65 and older, obtained from The Cancer Genome Atlas (TCGA). Kaplan-Meier survival analysis was performed to assess the impact of radiation therapy on survival. Correlations between genomic features, including mutation count, tumor mutational burden, and aneuploidy score, and overall survival were examined. Descriptive statistics were used to summarize patient demographics and treatment patterns.
Results Radiation therapy was associated with a higher mean survival (10.3 months) compared to patients who did not receive radiation (6.2 months). Genomic factors, such as mutation count and tumor mutational burden, showed weak negative correlations with survival. Despite the overall poor prognosis, radiation therapy appeared to modestly improve survival in this cohort.
Conclusions Our findings highlight the potential benefits of radiation therapy for older glioblastoma patients, even in the context of frailty and comorbidities. Further research is needed to explore how genomic markers can inform personalized treatment strategies and improve outcomes in this population.
Simple Summary Glioblastoma is an aggressive brain cancer that disproportionately affects older adults, a group often excluded from clinical trials. This study aims to examine how treatment approaches, such as radiation therapy and tumor characteristics, influence survival outcomes in glioblastoma patients aged 65 and older. By analyzing clinical and genomic data, we hope to identify factors that may improve treatment strategies and outcomes for this vulnerable population. Our findings could help guide healthcare professionals in making more personalized and effective treatment decisions for older patients, potentially improving their quality of life and survival.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: https://www.cbioportal.org
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
andrew.Ibrahim{at}ttuhsc.edu
kansari{at}ehoftexas.com
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.